Is Alexion Pharmaceuticals a Buy?
Alexion Pharmaceuticals (NASDAQ: ALXN) develops therapies solely for rare diseases, so you probably haven't heard of most of the conditions that it makes drugs for. However, for investors, it's worth paying attention to because of how effective it is at penetrating its target markets. For example, within 18 months of obtaining FDA approval for its paroxysmal nocturnal hemoglobinuria treatment, Ultomiris, Alexion had enrolled 70% of the eligible U.S. patient population with the disease.
That's not the only thing for investors to appreciate about Alexion, however. Given its extensive drug-candidate pipeline, stable revenue growth, positive outlook, and some new investor-friendly policies, it's probably worth adding to your portfolio.
Image source: Getty Images.
Source Fool.com
